Sole Source Procurement for MyCare Psychiatry Clozapine Assay Kit and Controls from Saladax Biomedic

The State of Oregon is issuing a sole source procurement notification for the purchase of MyCare Psychiatry Clozapine Assay Kit and Controls from Saladax Biomedical. This procurement is classified as a sole source acquisition, meaning competitive bidding has been determined impracticable due to the proprietary nature of the testing system and its unique integration requirements with existing laboratory infrastructure. The goods being procured include specialized laboratory testing equipment and materials—specifically the MyCare Psychiatry Clozapine Assay Kit and associated controls—which are essential for psychiatric patient monitoring and drug level testing within Oregon's healthcare operations. The primary objective is to maintain uninterrupted psychiatric patient testing capabilities by acquiring the assay kits and controls necessary to support the state's clinical laboratory operations. The procurement notification was posted on May 4, 2026, with a response deadline of May 11, 2026, providing a one-week timeframe for interested parties to submit inquiries or comments. Saladax Biomedical has been identified as the sole source vendor capable of meeting the specific technical requirements, as no other vendor can provide products with equivalent specifications and compatibility with the existing MyCare Psychiatry system infrastructure.

The sole source justification document indicates that Saladax Biomedical is the only qualified provider for this specialized assay kit and controls due to proprietary system requirements and technical specifications that preclude competition from alternative vendors. The procurement approach allows Oregon to proceed directly with the selected vendor without the extended timeline typically associated with competitive bidding processes, thereby avoiding potential delays in maintaining critical psychiatric patient testing services. No set-aside designations for disadvantaged enterprises or other socioeconomic categories are referenced in the available procurement documentation. Saladax Biomedical is identified as the incumbent and sole-source vendor, with the procurement specifically designed to ensure continuity of the MyCare Psychiatry testing platform already integrated into Oregon's laboratory infrastructure. The specific award value or budget range for this procurement has not been disclosed in the available documentation; however, the procurement is anticipated to cover the cost of assay kits and associated control materials necessary to sustain ongoing psychiatric patient monitoring operations.